Gilead Sciences (GILD) DIvidends Date & History

Key Takeaways

• Gilead Sciences (GILD) offers a current dividend yield of approximately 2.5% with an annual dividend of $3.28 per share.
• The company pays dividends quarterly and has increased its payout for 10 consecutive years.
• Payout ratio stands at roughly 44%, indicating strong earnings coverage and sustainability.
• Recent quarterly dividend of $0.82 reflects a 3.8% increase announced in early 2026.
• The dividend profile appeals to investors seeking moderate income with growth potential in the healthcare sector.
• Free cash flow supports consistent payments without straining the balance sheet.

Dividend Overview

Gilead Sciences (GILD) maintains a quarterly dividend policy that provides investors with regular income. The current annual dividend totals $3.28 per share, delivering a yield near 2.5% based on recent share prices. Payments occur four times per year, with the most recent ex-dividend date on June 15, 2026. The company is viewed as a dividend growth stock rather than a high-yield play, offering modest but reliable returns alongside potential capital appreciation in the biotechnology sector.

Dividend History and Growth

Gilead Sciences (GILD) initiated regular dividend payments more than a decade ago and has maintained a consistent growth trajectory. The quarterly dividend has risen steadily, with a notable 3.8% increase to $0.82 per share effective in the first quarter of 2026. Over the past decade, annualized dividend growth has averaged around 6%, reflecting disciplined capital allocation. The company has delivered 10 consecutive years of dividend increases, underscoring a long-term commitment to returning capital to shareholders through growing payouts.

Dividend Sustainability and Payout Ratio

The dividend appears well-supported by fundamentals. Gilead Sciences (GILD) reports a payout ratio of approximately 44%, meaning earnings comfortably cover the dividend with substantial room for reinvestment or further increases. Strong free cash flow generation in its core antiviral and oncology businesses provides additional coverage. Debt levels remain manageable, and the company’s overall financial stability supports ongoing dividend payments without reliance on external financing. Future increases remain subject to board approval but align with historical patterns of prudent growth.

Dividend Compared to Industry Peers

Within the healthcare and biotechnology sector, Gilead Sciences (GILD) dividend yield of about 2.5% exceeds the industry average of roughly 1.6%. Peers in large-cap pharmaceuticals often deliver lower yields but similar growth profiles. This positions (GILD) as an attractive option for investors seeking above-average income within the sector while maintaining exposure to innovative drug development pipelines.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to refine your investment ideas.

Is This Stock Attractive for Dividend Investors?

Gilead Sciences (GILD) may suit income-oriented investors who value a moderate yield combined with a proven dividend growth record. Conservative long-term holders could appreciate the quarterly payment schedule and earnings coverage that supports sustainability. Dividend growth investors may find the 10-year increase streak appealing, though the yield remains modest compared with higher-yielding sectors. The stock’s profile balances income generation with exposure to biotechnology innovation, making it potentially suitable for diversified portfolios focused on healthcare. Investors should evaluate personal objectives and risk tolerance before considering any position.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations